Page last updated: 2024-09-23

ibopamine

Description

ibopamine: structure given in UD 31;67a & in 2nd source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID68555
CHEMBL ID307739
CHEBI ID135306
SCHEMBL ID147258
MeSH IDM0080783

Synonyms (37)

Synonym
CHEMBL307739
trazyl
sb-7505
ibopamine
4-[2-(methylamino)ethyl]benzene-1,2-diyl bis(2-methylpropanoate)
ibopamine (usan/inn)
D04488
66195-31-1
propanoic acid, 2-methyl-, 4-(2-(methylamino)ethyl)-1,2-phenylene ester
ibopamino [inn-spanish]
einecs 266-229-5
sb 7505
4-(2-(methylamino)ethyl)-2-phenylendiisobutyrat
skf 100168
ibopaminum [inn-latin]
4-(2-(methylamino)ethyl)-o-phenylene diisobutyrate
L013392
CHEBI:135306
[4-[2-(methylamino)ethyl]-2-(2-methylpropanoyloxy)phenyl] 2-methylpropanoate
8zca2i2l11 ,
ibopamine [usan:inn:ban]
unii-8zca2i2l11
ibopaminum
ibopamino
4-[2-(methylamino)ethyl]-o-phenylene diisobutyrate
ibopamine [inn]
ibopamine [usan]
ibopamine [mart.]
ibopamine [who-dd]
ibopamine [mi]
SCHEMBL147258
DTXSID3023138
5-[2-(methylamino)ethyl]-2-[(2-methylpropanoyl)oxy]phenyl 2-methylpropanoate
Q5984366
DB13316
4-(2-(methylamino)ethyl)-1,2-phenylene bis(2-methylpropanoate)
sb 7505; sb 7505 (pharmaceutical); skf 100168

Research Excerpts

Overview

ExcerptReference
"An ibopamine challenge is a novel technique for assessing glaucoma using ibopamine, a topical drug which temporarily increases aqueous production. "( Craig, JE; Landers, J; Ullrich, K, 2015)
"Ibopamine is a prodrug of epinine (deoxyepinephrine) that exhibits activity at dopaminergic and adrenergic receptors. "( Brubaker, RF; Ciarniello, MG; Dionisio, P; Herman, DC; McLaren, JW; Nau, CB; Rosignoli, MT; Wayman, LL, 2003)
"Ibopamine is a non-selective dopamine- and adrenalin-receptor agonist that has been shown to cause pupillary dilation and an increase in aqueous humour secretion. "( Iliev, ME; Windisch, BK, 2006)
"Ibopamine is an alpha-adrenergic agent and causes an elevation of intraocular pressure in eyes with increased outflow resistance. "( Gloor, BP; Kniestedt, C; Romppainen, T; Stürmer, J, 2007)
"Ibopamine is an orally active dopamine agonist (DA) with both hemodynamic and neurohumoral properties in humans."( Buikema, H; de Graeff, PA; Hegeman, H; Lie, KI; Scholtens, E; van Gilst, WH; van Veldhuisen, DJ, 1994)
"Ibopamine is an original dopamine analogue. "( Galbiati, I; Gazzaniga, A; Gianesello, V; Soldati, L; Virno, M, 1993)
"Ibopamine is an active dopamine analogue leading to improved renal perfusion and afterload reduction in heart failure. "( Cabell, B; Glogar, D; Kleber, FX; Sabin, GV; Thyroff-Friesinger, U, 1992)
"Ibopamine is an orally active derivative of dopamine (DA) which metabolizes to its active form, epinine. "( Itoh, H, 1991)
"Ibopamine is a new, orally active drug with a predominant action on dopaminergic adrenoceptors."( Man in't Veld, AJ, 1991)
"Ibopamine is a dopamine-like drug that shows mainly vasoactive properties, predominantly acting on dopamine1-(DA1-) and DA2-adrenoceptors. "( López-Sendón, J, 1991)
"Ibopamine (IP) is a novel dopamine analogue for which beneficial effects have been shown in chronic heart failure. "( Theisen, K; Wehling, M, 1991)
"Ibopamine is a dopamine-related drug active by oral route, namely the diisobutyric ester of N-methyl-dopamine."( Marchetti, GV, 1990)
"Ibopamine is an orally active dopaminergic substance and acts mainly as a vasodilator in patients with heart failure."( Storstein, L, 1990)
"Ibopamine is a new, orally active dopamine-like drug with inotropic and vasoactive properties. "( López-Sendón, J, 1990)
"1. Ibopamine is a new orally active inodilator, which is developed for the treatment of congestive heart failure (CHF). "( Crijns, HJ; de Graeff, PA; Girbes, AR; Lie, KI; Smit, AJ; van Veldhuisen, DJ, 1990)
"Ibopamine is a novel oral dopamine analogue with positive inotropy and diuretic effects. "( Gerzer, R; Theisen, K; Wehling, M; Weil, J; Zimmermann, J, 1990)
"Ibopamine is a novel oral dopamine analogue with vasodilatory, positive inotropic and diuretic effects. "( Theisen, K; Wehling, M; Zimmermann, J, 1990)
"Ibopamine is a dopaminergic and adrenergic receptor agonist, which is active in the treatment of congestive heart failure. "( , 1989)
"Ibopamine is a new orally active dopamine analogue with positive inotropic and vasodilating activity. "( Abbondati, G; Cavalli, A; Cedrini, MC; Fuccella, LM; Riva, E; Schleman, M, 1989)
"Ibopamine is an orally active derivative of dopamine which undergoes hydrolysis to the active moiety epinine. "( Henwood, JM; Todd, PA, 1988)
"Ibopamine is an orally effective derivative of dopamine capable of eliciting peripheral and renal vasodilating activity and positive inotropic action. "( Bussmann, WD; Frik, R; Wienhöfer, K, 1988)
"Ibopamine is a new dopamine derivative, active on dopaminergic and beta-adrenergic receptors, whose hemodynamic activity has been acutely demonstrated."( Dei Cas, L; Manca, C; Metra, M; Nodari, S; Riva, S; Visioli, O, 1988)

Effects

ExcerptReference
"Ibopamine has hemodynamic and neurohumoral effects potentially useful for the treatment of congestive heart failure (CHF), but its mechanism of action is not completely clear. "( Cas, LD; Metra, M; Missale, C; Spano, PF, 1995)
"Ibopamine has varying degrees of affinity for these various families, being the highest for the dopamine receptors and the lowest for the alpha adrenergic receptors."( Pouleur, H, 1995)
"Ibopamine has been shown to be a safe and useful drug added to conventional treatment of cardiac heart failure."( Astorga, MA; Ceia, F; Coelho, EM; Fonseca, C; Gil, V; Gomes, RS; Gouveia, R; Luís, AS; Mota, E; Riva, E, 1992)
"Ibopamine has proved to be safe in many thousands of heart failure patients during long-term therapy."( Man in't Veld, AJ, 1991)
"Ibopamine has potential in improving prognosis by its major effects: vasodilatation, decrease in vasoactive hormones and improvement in renal blood flow and water diuresis."( Kleber, FX, 1991)

Actions

ExcerptReference
"Ibopamine seems to increase the risk of death among patients with advanced heart failure who are already receiving optimum therapy, but the reasons for this increase are not clear. "( Ardia, A; Block, P; Cortina, A; Cowley, AJ; Cserhalmi, L; Follath, F; Hampton, JR; Jensen, G; Kayanakis, J; Kleber, FX; Lie, KI; Mancia, G; Skene, AM; van Veldhuisen, DJ, 1997)
"Ibopamine was found to increase cardiac output and stroke index and to decrease systemic vascular resistance in this acute study."( Itoh, H; Koike, A; Nakamura, S; Sato, Y; Taniguchi, K; Tsujibayashi, T, 1992)
"Ibopamine is able to activate dopamine specific and adrenergic receptors in the heart and circulation, inducing a vasodilating activity together with a mild positive inotropic effect without increasing heart rate and myocardial O2 consumption."( Marchetti, GV, 1990)
"Ibopamine does not produce undesirable renal side effects, but affects the neurohumoral status favourably."( Theisen, K; Wehling, M; Zimmermann, J, 1990)
"Ibopamine had a slower but more prolonged effect on cardiac output (increase of up to 32.1% at 60 min) and systemic vascular resistances."( Compostella, L; Cucchini, F; Di Mario, C; Ghirardi, P; Iavernaro, A; Libardoni, M, 1990)
"Ibopamine caused an increase in mean estimated stroke volume (SV +29% for the maximum change from baseline and +15% cumulatively over the first h) with no change in mean heart rate (HR) or QTc."( Brendel, E; de Mey, C; Enterling, D; Wesche, H, 1988)

Treatment

ExcerptReference
"Ibopamine treatment was ineffective in Group 2, while in Group 1 patients there was a statistically significant increase in creatinine clearance (+23% after 3 months, +31% after 6 months)."( Colí, L; Docci, D; Mosconi, G; Prandini, R; Stefoni, S; Vangelista, A, 1982)
"Ibopamine-treatment, which resulted in peak plasma epinine concentrations of 4-5 nmol.l-1, neither affected resting heart rate or blood pressure, nor any of the alpha- or beta-adrenoceptor parameters measured."( Boomsma, F; Brodde, OE; Klusmann, I; Man in't Veld, AJ; Michel, MC; Wojcik, M, 1993)

Drug Classes (2)

ClassDescription
phenolsOrganic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring.
benzoate esterEsters of benzoic acid or substituted benzoic acids.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (19)

Assay IDTitleYearJournalArticle
AID496828Antimicrobial activity against Leishmania donovani2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID409942Inhibition of human recombinant MAOA by fluorimetric method2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID496829Antimicrobial activity against Leishmania infantum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496817Antimicrobial activity against Trypanosoma cruzi2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID497005Antimicrobial activity against Pneumocystis carinii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID409943Inhibition of human recombinant MAOB by fluorimetric method2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID496832Antimicrobial activity against Trypanosoma brucei rhodesiense2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496818Antimicrobial activity against Trypanosoma brucei brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496827Antimicrobial activity against Leishmania amazonensis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496831Antimicrobial activity against Cryptosporidium parvum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496820Antimicrobial activity against Trypanosoma brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496825Antimicrobial activity against Leishmania mexicana2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID40531Positive inotropic effects by direct or indirect beta-1 adrenergic receptor activation.1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
In search of the digitalis replacement.
AID496821Antimicrobial activity against Leishmania2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496824Antimicrobial activity against Toxoplasma gondii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496826Antimicrobial activity against Entamoeba histolytica2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496823Antimicrobial activity against Trichomonas vaginalis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496830Antimicrobial activity against Leishmania major2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (287)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990131 (45.64)18.7374
1990's120 (41.81)18.2507
2000's26 (9.06)29.6817
2010's9 (3.14)24.3611
2020's1 (0.35)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials87 (27.71%)5.53%
Reviews38 (12.10%)6.00%
Case Studies13 (4.14%)4.05%
Observational1 (0.32%)0.25%
Other175 (55.73%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research Highlights

Safety/Toxicity (3)

ArticleYear
Safety of ibopamine in type II diabetic patients with mild chronic heart failure. A double-blind cross-over study.
Cardiology, Volume: 77 Suppl 5
1990
The safety profile of ibopamine, an alternative substance for treatment of chronic heart failure.
Cardiology, Volume: 77 Suppl 5
1990
Safety of ibopamine therapy in congestive heart failure. Ibopamine cohort study: baseline and 1-year results.
Arzneimittel-Forschung, Volume: 41, Issue: 4
1991
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Long-term Use (4)

ArticleYear
Lack of desensitization of alpha- and beta-adrenoceptor function during chronic treatment of healthy volunteers with ibopamine, an orally active dopamine receptor agonist.
European journal of clinical pharmacology, Volume: 44, Issue: 3
1993
The effects of ibopamine on glomerular filtration rate and plasma norepinephrine remain preserved during prolonged treatment in patients with congestive heart failure.
European heart journal, Volume: 16, Issue: 7
1995
Hemodynamic evaluation during exercise test after acute and chronic ibopamine treatment in patients with congestive heart failure.
Arzneimittel-Forschung, Volume: 36, Issue: 2A
1986
Hemodynamic and neurohumoral effects of ibopamine in patients with chronic congestive heart failure.
Cardiology, Volume: 77 Suppl 5
1990
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Pharmacokinetics (11)

ArticleYear
Ocular pharmacokinetics and pharmacodynamics in rabbits of ibopamine, a new mydriatic agent.
Experimental eye research, Volume: 56, Issue: 2
1993
Acute effect of ibopamine and isosorbide mononitrate on blood volume distribution in congestive heart failure.
European journal of clinical pharmacology, Volume: 47, Issue: 4
1994
Evaluation of acute hemodynamic effects and pharmacokinetic behaviour of ibopamine in patients with severe heart failure.
Arzneimittel-Forschung, Volume: 36, Issue: 2A
1986
Ibopamine, an orally active dopamine-like drug: metabolism and pharmacokinetics in rats.
Arzneimittel-Forschung, Volume: 36, Issue: 2A
1986
Ibopamine (SK&F 100168) pharmacokinetics in relation to the timing of meals.
British journal of clinical pharmacology, Volume: 23, Issue: 5
1987
Pharmacokinetics of ibopamine in patients with renal impairment.
International journal of clinical pharmacology, therapy, and toxicology, Volume: 26, Issue: 2
1988
Pharmacokinetics and pharmacodynamics of single oral doses of ibopamine, quinidine and their combination in normal man.
European journal of clinical pharmacology, Volume: 34, Issue: 4
1988
Clinical pharmacokinetics of ibopamine on different diseases and conditions.
Arzneimittel-Forschung, Volume: 38, Issue: 8
1988
Pharmacokinetic and pharmacodynamic interactions between single oral doses of ibopamine and food in normal man.
Arzneimittel-Forschung, Volume: 39, Issue: 9
1989
Hemodynamic effects and pharmacokinetics of long-term therapy with ibopamine in patients with chronic heart failure.
Cardiology, Volume: 80, Issue: 5-6
1992
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioavailability (3)

ArticleYear
Ocular pharmacokinetics and pharmacodynamics in rabbits of ibopamine, a new mydriatic agent.
Experimental eye research, Volume: 56, Issue: 2
1993
Study of the bioequivalence of three oral formulations of ibopamine in healthy volunteers.
International journal of clinical pharmacology, therapy, and toxicology, Volume: 26, Issue: 10
1988
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Dosage (24)

ArticleYear
Comparative study of the effects of 2% ibopamine, 10% phenylephrine, and 1% tropicamide on the anterior segment.
Investigative ophthalmology & visual science, Volume: 44, Issue: 1
2003
Low-dosage ibopamine treatment in progressive renal failure: a long-term multicentre trial.
American journal of nephrology, Volume: 16, Issue: 6
1996
Hemodynamic evaluation during exercise test after acute and chronic ibopamine treatment in patients with congestive heart failure.
Arzneimittel-Forschung, Volume: 36, Issue: 2A
1986
The diisobutyryl ester of N-methyldopamine, ibopamine: evaluation of electrophysiological properties and arrhythmogenicity studies.
Arzneimittel-Forschung, Volume: 36, Issue: 2A
1986
Ibopamine (SK&F 100168) pharmacokinetics in relation to the timing of meals.
British journal of clinical pharmacology, Volume: 23, Issue: 5
1987
Acute effects of ibopamine hydrochloride on hemodynamics, plasma catecholamine levels, renin activity, aldosterone, metabolism and blood gas in patients with severe congestive heart failure.
Arzneimittel-Forschung, Volume: 36, Issue: 12
1986
Pharmacokinetics of ibopamine in patients with renal impairment.
International journal of clinical pharmacology, therapy, and toxicology, Volume: 26, Issue: 2
1988
Ibopamine kinetics after a single oral dose in patients with congestive heart failure.
International journal of clinical pharmacology, therapy, and toxicology, Volume: 26, Issue: 2
1988
Systemic and coronary hemodynamic actions of the novel inotropic agent, ibopamine, and the de-esterified metabolite and active form, epinine: relationship to left ventricular performance in the dog.
The Journal of pharmacology and experimental therapeutics, Volume: 246, Issue: 2
1988
Pharmacokinetics and pharmacodynamics of single oral doses of ibopamine, quinidine and their combination in normal man.
European journal of clinical pharmacology, Volume: 34, Issue: 4
1988
Ibopamine kinetics after single and multiple dosing in patients with congestive heart failure.
International journal of clinical pharmacology, therapy, and toxicology, Volume: 26, Issue: 11
1988
Effects of ibopamine in combination with furosemide on renal function in patients with chronic congestive heart failure.
International journal of clinical pharmacology, therapy, and toxicology, Volume: 26, Issue: 7
1988
Clinical pharmacokinetics of ibopamine on different diseases and conditions.
Arzneimittel-Forschung, Volume: 38, Issue: 8
1988
Comparison of the effects of the novel inotropic agent, ibopamine, with epinine, dopamine and fenoldopam on renal vascular dopamine receptors in the anesthetized dog.
The Journal of pharmacology and experimental therapeutics, Volume: 242, Issue: 2
1987
Pharmacokinetic and pharmacodynamic interactions between single oral doses of ibopamine and food in normal man.
Arzneimittel-Forschung, Volume: 39, Issue: 9
1989
Clinical relevance of long-term therapy with levodopa and orally active dopamine analogues in patients with chronic congestive heart failure.
Basic research in cardiology, Volume: 84 Suppl 1
1989
Ibopamine vs. digoxin in chronic heart failure: a double-blind, crossover study.
Journal of cardiovascular pharmacology, Volume: 14 Suppl 8
1989
Efficacy of ibopamine treatment in patients with advanced heart failure: purpose of a new therapeutic scheme with multiple daily administrations.
Journal of cardiovascular pharmacology, Volume: 14 Suppl 8
1989
Safety of ibopamine in type II diabetic patients with mild chronic heart failure. A double-blind cross-over study.
Cardiology, Volume: 77 Suppl 5
1990
[Ibopamine--pharmacologic principles].
Zeitschrift fur Kardiologie, Volume: 80 Suppl 8
1991
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]